Delcath Systems to Hold Q1 2024 Earnings Call

Delcath Systems, Inc., an interventional oncology firm focusing on primary and metastatic liver cancer treatment, has scheduled a conference call on May 14, 2024, at 8:30 AM Eastern Time. The company will discuss its financial results for the first quarter ending March 31, 2024.

Delcath Systems specializes in liver cancer treatments through its proprietary products: the HEPZATO KIT and CHEMOSAT Hepatic Delivery System. The HEPZATO KIT, a combination of the chemotherapeutic agent melphalan and Delcath's Hepatic Delivery System (HDS), is designed to administer high doses of chemotherapy directly to the liver while minimizing systemic exposure and potential side effects. This method is known as percutaneous hepatic perfusion (PHP) and involves isolating the liver and filtering hepatic venous blood during melphalan administration and washout. This technique aims to deliver a substantial dose of melphalan to the liver, which can induce a significant tumor response with limited hepatotoxicity and reduced systemic exposure.

In the United States, the HEPZATO KIT is approved by the FDA as a treatment for adult patients with metastatic uveal melanoma (mUM) who have unresectable hepatic metastases involving less than 50% of the liver. These patients must also have no extrahepatic disease or only limited extrahepatic disease restricted to the bone, lymph nodes, subcutaneous tissues, or lungs that can be treated with resection or radiation. The product is regulated as a combination drug and device, ensuring strict oversight and approval for sale as a pharmaceutical product.

In Europe, the device-only version of the HDS, marketed under the name CHEMOSAT, is regulated as a Class III medical device. It is approved for sale and is utilized in major medical centers for performing percutaneous hepatic perfusion procedures to treat a wide variety of liver cancers. The European version of CHEMOSAT has contributed significantly to the treatment landscape by providing a specialized method for delivering high-dose chemotherapy directly to the liver, thereby enhancing the effectiveness of cancer treatment while controlling systemic toxicity.

For those interested in participating in the conference call, it is recommended to dial in 5 to 10 minutes before the scheduled start time. The event details are as follows:
- Event Date: Tuesday, May 14, 2024
- Time: 8:30 AM Eastern Time
- Toll Free Number: 1-833-630-1960
- International Number: 1-412-317-1841

The HEPZATO KIT and CHEMOSAT systems represent significant advancements in the field of interventional oncology, particularly for the treatment of liver cancers. These products offer a targeted treatment approach, reducing systemic side effects and potentially improving patient outcomes. Delcath Systems continues to innovate in this space, providing advanced solutions for challenging cancer treatments.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!